Table 2.
Clinicopathological features and NFATc1 expression in patients with stage IE/IIE1 gastric MALT lymphoma who received first-line HPE therapy
| Nuclear localization of NFATc1 | |||||
|---|---|---|---|---|---|
| Clinicopathological characteristics | Total number (n = 91) | Presence (n = 51) |
Absence (n = 40) |
p* | |
| Age (median, range, years) | 56.0 (20–86) | 57.0 (30–83) | 55.0 (20–86) | 0.608# | |
| Sex, men/women | 38/53 | 21/30 | 17/23 | 0.899§ | |
| Endoscopic features, n (%) | 0.289‡ | ||||
|
Gastritis-like or multiple erosion on infiltrative mucosa |
35 (38%) | 19 (37%) | 16 (40%) | ||
| Ulceration or ulcerated mass | 40 (44%) | 20 (39%) | 20 (50%) | ||
| Erosions on giant nodular folds | 16 (18%) | 12 (24%) | 4 (10%) | ||
| Location of lymphoma(s), n (%) | 0.570§ | ||||
| Proximala or ≥ 2 components | 29 (32%) | 15 (29%) | 14 (35%) | ||
| Distalb | 62 (68%) | 36 (71%) | 26 (65%) | ||
| Stage | 0.537§ | ||||
| IE | 70 (77%) | 38 (75%) | 32 (80%) | ||
| IIE1 | 21 (23%) | 13 (25%) | 8 (20%) | ||
| Depth of gastric wall involvement, n (%)¶ | 0.380§ | ||||
| Submucosa or above | 52/86 (60%) | 31/48 (65%) | 21/38 (55%) | ||
| Muscularis propria or beyond | 34/86 (40%) | 17/48 (35%) | 17/38 (45%) | ||
| CagA expression | < 0.001§ | ||||
| Positive | 54 (59%) | 41 (80%) | 13 (33%) | ||
| Negative | 37 (41%) | 10 (20%) | 27 (67%) | ||
| T(11;18)(q21;q21)/BIRC3-MALT1 | 0.002 | ||||
| Positive | 10 (11%) | 1 (2%) | 9 (23%) | ||
| Negative | 81 (89%) | 50 (98%) | 31 (77%) | ||
p*: comparison of discrete variables between NFATc1-positive cases and NFATc1-negative cases
#p values (two-sided) were calculated using the Student’s t-test
§p values (two-sided) were calculated using Chi-square test or Fisher’s exact test
‡p values (two-sided) were calculated using one-way analysis of variance
Proximala: Middle body, upper body, fundus, or cardia. Distalb: Antrum, angle, or lower body
Gastric wall involvement was evaluated by endoscopic ultrasonography in 86 patients
HPE Helicobacter pylori eradication therapy, MALT mucosa-associated lymphoid tissue